Computational Studies in Drug Design against Cancer.

BACKGROUND The application of in silico tools in the development of anti cancer drugs. Objective: The summing of different computer aided drug design approaches that have been applied in the development of anti cancer drugs. Method: Structure based, ligand based, hybrid protein-ligand pharmacophore methods, Homology modeling, molecular docking aids in different steps of drug discovery pipeline with considerable saving in time and expenditure. In silico tools also finds applications in the domain of cancer drug development. Results: Structure-based pharmacophore modeling aided in the identification of PUMA inhibitors, structure based approach with high throughput screening for the development of Bcl-2 inhibitors, to derive the most relevant protein-protein interactions, anti mitotic agents; I-Kappa-B Kinase β (IKK- β) inhibitor, screening of new class of aromatase inhibitors that can be important targets in cancer therapy. Conclusion: Application of computational methods in the design of anti cancer drugs was found to be effective.

[1]  I. Bahar,et al.  Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. , 2009, Journal of medicinal chemistry.

[2]  A. Mai,et al.  Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells. , 2017, European journal of medicinal chemistry.

[3]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[4]  Sungpil Yoon,et al.  The JAK2 inhibitors CEP-33779 and NVP-BSK805 have high P-gp inhibitory activity and sensitize drug-resistant cancer cells to vincristine. , 2017, Biochemical and biophysical research communications.

[5]  A. Siddique,et al.  The olive oil phenolic (‐)‐oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment , 2017, European journal of pharmacology.

[6]  Sk Abdul Amin,et al.  Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study. , 2017, European journal of medicinal chemistry.

[7]  Francisco Azuaje,et al.  Computational models for predicting drug responses in cancer research , 2016, Briefings Bioinform..

[8]  S. Noha,et al.  Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques , 2011, Bioorganic & medicinal chemistry letters.

[9]  Theodora Katsila,et al.  Computational approaches in target identification and drug discovery , 2016, Computational and structural biotechnology journal.

[10]  Jian Yu,et al.  PUMA, a potent killer with or without p53 , 2008, Oncogene.

[11]  Mohsen Shahlaie,et al.  Development of a human epidermal growth factor derivative with EGFR-blocking and depleted biological activities: A comparative in vitro study using EGFR-positive breast cancer cells. , 2017, International journal of biological macromolecules.

[12]  W. Pangborn,et al.  Structural basis for androgen specificity and oestrogen synthesis in human aromatase , 2009, Nature.

[13]  Abdul Wadood,et al.  -Drug Design In-silico drug design: An approach which revolutionarised the drug discovery process , 2013 .

[14]  Junfeng Shi,et al.  Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer , 2017, Journal of cellular and molecular medicine.

[15]  P. Scheet,et al.  Cancer In Silico Drug Discovery: A Systems Biology Tool for Identifying Candidate Drugs to Target Specific Molecular Tumor Subtypes , 2014, Molecular Cancer Therapeutics.

[16]  G. Mustata,et al.  Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). , 2010, Bioorganic & medicinal chemistry letters.

[17]  P. Workman,et al.  Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.

[18]  R. Premkumar,et al.  Spectroscopic and molecular docking studies on N,N-di-tert-butoxycarbonyl (Boc)-2-amino pyridine: A potential bioactive agent for lung cancer treatment , 2017 .

[19]  Ivet Bahar,et al.  Development of small-molecule PUMA inhibitors for mitigating radiation-induced cell death. , 2011, Current topics in medicinal chemistry.

[20]  Xuan Yang,et al.  Synthesis and biological evaluation of α-methyl-chalcone for anti-cervical cancer activity , 2017, Medicinal Chemistry Research.

[21]  Ping-Chiang Lyu,et al.  Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. , 2009, Journal of medicinal chemistry.

[22]  F. Khan,et al.  3D-QSAR studies on Maslinic acid analogs for Anticancer activity against Breast Cancer cell line MCF-7 , 2017, Scientific Reports.

[23]  S. C. Araujo,et al.  Study on molecular structure, spectroscopic properties (FTIR and UV-Vis), NBO, QTAIM, HOMO-LUMO energies and docking studies of 5-fluorouracil, a substance used to treat cancer. , 2017, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[24]  E. Prochownik,et al.  Differential apoptotic behaviors of c-myc, N-myc, and L-myc oncoproteins. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[25]  Rezaul Karim,et al.  Use of computer in drug design and drug discovery: A review , 2012 .

[26]  G Maithri,et al.  Computational Drug Design and Molecular Dynamic Studies-A Review , 2017 .

[27]  Yi-Wei Chang,et al.  Structure–Activity Relationship Studies of 3‐Aroylindoles as Potent Antimitotic Agents , 2006, ChemMedChem.

[28]  K. Srinivasan,et al.  In Silico Drug-Designing Studies on Flavanoids as Anticolon Cancer Agents: Pharmacophore Mapping, Molecular Docking, and Monte Carlo Method-Based QSAR Modeling , 2017, Interdisciplinary Sciences: Computational Life Sciences.

[29]  S. Singh,et al.  Chemopreventive effect of saponin isolated from Gymnema sylevestre on prostate cancer through in silico and in vivo analysis , 2017, Medicinal Chemistry Research.